AdvancedCPR Solutions
- Industry
- Medical Devices
- Founded Year
- 2015
- Headquarters
- Edina, Minnesota
- Employee Count
- 0
Key People
- Philip W. Faris - Founder, CEO & Director
- Keith G. Lurie, M.D. - Founder, CMO & Director
- Glenn Robinson, CPA - Chief Financial Officer
- Anja Metzger, PhD - VP Clinical and Preclinical Affairs
- Kim Marie Macygin, MSN, RN, CEN - Vice President of Clinical Education
- Lisa M. Owens - Vice President Marketing Strategy & Communications
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises seasoned professionals with extensive experience in medical device innovation and commercialization.
The co-founders and executive team have a history of developing and introducing disruptive medical devices globally, indicating strong leadership and industry expertise.
- Clinical Need
-
Aspect: Very Strong
Summary: Sudden cardiac arrest (SCA) is a leading cause of death worldwide, necessitating innovative solutions to improve survival rates.
The EleGARD Patient Positioning System aims to enhance CPR effectiveness, potentially increasing neurologically-intact survival rates from SCA.
- Competition
-
Aspect: Somewhat crowded
Summary: The market for CPR devices includes several established players, but the EleGARD system offers unique features.
While competitors exist, the EleGARD system's precise patient positioning for ElevatedCPR method may provide a competitive edge.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing a device that integrates seamlessly with existing CPR protocols and equipment presents moderate technical challenges.
The EleGARD system must function effectively with manual and automated CPR devices, requiring careful design and testing.
- Patent
-
Aspect: Very Strong
Summary: The company holds broad method patents for ElevatedCPR therapy, providing robust intellectual property protection.
The issued patents cover the method of performing CPR with head and thorax elevation, safeguarding the company's innovation.
- Financing
-
Aspect: Medium
Summary: Specific details about the company's funding are not publicly disclosed.
While the company is actively commercializing its product, the lack of disclosed funding details makes it challenging to assess financial stability.
- Regulatory
-
Aspect: 510k/PMA
Summary: The EleGARD system has received FDA 510(k) clearance and CE marking, allowing for commercial distribution.
The device's clearance for expanded indications demonstrates compliance with regulatory standards and readiness for broader clinical use.
Opportunity Rollup
- Odds of Success
- 4.15
- Peak Market Share
- 5.45
- Segment CAGR
- 5.8%
- Market Segment
- Cardiovascular Devices
- Market Sub Segment
- Cardiac Assist Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.27 |
| 2 | 0.82 |
| 3 | 1.91 |
| 4 | 3.82 |
| 5 | 5.45 |
Key Takeaway
AdvancedCPR Solutions, with its experienced team and patented EleGARD system, is well-positioned to address the critical need for improved cardiac arrest survival rates, despite facing a competitive market and financial disclosure challenges.